No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents

JACC: Cardiovascular Interventions

Volumn 2, Issue 11, 2009, Pages 1149-1155

  Hoppmann, Petra ^a   Erl, Anna ^a   Türk, Serin ^a   Tiroch, Klaus ^a   Mehilli, Julinda ^a   Schömig, Albert ^a   Kastrati, Adnan ^a   Koch, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

atherosclerosis; coronary artery disease; drug eluting stents; genetics; restenosis; single nucleotide polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CHROMOSOME 9P; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; DEATH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC ASSOCIATION; GENOME ANALYSIS; GENOME SIZE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CHROMOSOMES, HUMAN, PAIR 9; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70449464762     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.08.021     Document Type: Article

References (32)

1. Morice M.-C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
4. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
5. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
6. Morice M.-C., Serruys P.W., Barragan P., et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 50 (2007) 1299-1304
7. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
8. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007) 661-678
9. McPherson R., Pertsemlidis A., Kavaslar N., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316 (2007) 1488-1491
10. Helgadottir A., Thorleifsson G., Manolescu A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316 (2007) 1491-1493
11. Samani N.J., Erdmann J., Hall A.S., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 357 (2007) 443-453
12. Broadbent H.M., Peden J.F., Lorkowski S., et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet 17 (2008) 806-814
13. Helgadottir A., Thorleifsson G., Magnusson K.P., et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 40 (2008) 217-224
14. Schunkert H., Götz A., Braund P., et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 117 (2008) 1675-1684
15. Ye S., Willeit J., Kronenberg F., Xu Q., and Kiechl S. Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis. J Am Coll Cardiol 52 (2008) 378-384
16. Coronary Artery Disease Consortium. Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol 29 (2009) 774-780
17. Ellis S.G., Vandormael M.G., Cowley M.J., et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 82 (1990) 1193-1202
18. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
19. Livak K.J. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 14 (1999) 143-149
20. Kutyavin I.V., Afonina I.A., Mills A., et al. 3'-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 28 (2000) 655-661
21. Horne B.D., Carlquist J.F., Muhlestein J.B., Bair T.L., and Anderson J.L. Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease. Circ Cardiovasc Genet 1 (2008) 85-92
22. Chen S.N., Ballantyne C.M., Gotto Jr. A.M., and Marian A.J. The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord 9 (2009) 3
23. Kotani J.-i., Awata M., Nanto S., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
24. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
25. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
26. Robertson K.D., and Jones P.A. Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 18 (1999) 3810-3820
27. Stone S., Dayananth P., Jiang P., et al. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 11 (1995) 987-991
28. Gil J., and Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7 (2006) 667-677
29. Kim W.Y., and Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 127 (2006) 265-275
30. Pasmant E., Laurendeau I., Héron D., Vidaud M., Vidaud D., and Bièche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67 (2007) 3963-3969
31. Yu W., Gius D., Onyango P., et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451 (2008) 202-206
32. Liu Y., Sanoff H.K., Cho H., et al. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One 4 (2009) e5027